MDMA-AT

Phase 3Small molecule

HHerzog Hospital

MDMA-AT is one of 7 small molecule programs targeting Bulimia Nervosa. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bulimia NervosaRecruiting

Bulimia NervosaPhase 1

Recruiting

Competition

Competitive Landscape

8 competitors in Bulimia Nervosa

#DrugCompanyPhaseTrials

Acetadote

AArbor Pharmaceuticals, Inc.

Prometrium

MDMA-AT

1 4

Lioresal

Novartis

Preclinical

1 5

Namenda

AbbVie

Preclinical

1 6

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

3 7

Benadryl

PParkedale

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Bulimia Nervosa

NCT07542145

Q4 2028

Phase 3Recruiting

Injury

NCT06394284

Clinical

Trials by Indication[1]

Injury1 trial

Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury

Recruiting·HHerzog Hospital·Phase 3·NCT06394284·60 enrolled

Bulimia Nervosa1 trial

MDMA Assisted Therapy for Bulimia Nervosa: A Treatment Development Protocol

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT07542145·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MDMA-AT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MDMA-AT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MDMA-AT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Herzog Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHerzog Hospital

MDMA-AT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Injury1 trial

Bulimia Nervosa1 trial

References

Drug Info

Quick Facts

Related News